GSK3145095 + pembrolizumab

GSK3145095 + pembrolizumab is a combination therapy studied for advanced solid tumors, especially pancreatic ductal adenocarcinoma. GSK3145095 is a small molecule inhibitor of receptor-interacting protein kinase 1 (RIPK1), designed to modulate the innate immune microenvironment in tumors and sensitize them to immune checkpoint inhibition. Pembrolizumab is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), a checkpoint inhibitor that enhances T-cell mediated antitumor responses. The combination has been evaluated in clinical trials for its ability to overcome immunosuppressive barriers in solid tumors, aiming to improve the efficacy of immunotherapy in disease settings resistant to single-agent checkpoint blockade[1][3][5][7].